Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
| Autor: | Herve Ghesquieres, Emmanuelle Ferrant, Clément Rocher, Violaine Safar, Frédérique Orsini-Piocelle, Claire Mauduit, Pierre Sesques, Delphine Maucort-Boulch, Arthur Dony, Juliette Fontaine, François-Xavier Gros, Anne Lazareth, Lionel Karlin, Cédric Rossi, Gian Matteo Pica, Alexandra Traverse-Glehen, Camille Golfier, Estelle Bourbon, Fadhela Bouafia, Clémentine Sarkozy, Marie Parrens, Emmanuel Bachy, Dana Ghergus |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Epstein-Barr Virus Infections
Herpesvirus 4 Human medicine.medical_specialty Lymphoid Neoplasia Palliative care CD30 Performance status business.industry Not Otherwise Specified Hazard ratio Ki-1 Antigen Retrospective cohort study Hematology medicine.disease Gastroenterology Lymphoma hemic and lymphatic diseases Internal medicine medicine Humans Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma Aged Retrospective Studies |
| Zdroj: | Blood Adv |
| ISSN: | 2473-9537 2473-9529 |
| Popis: | In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, median age was 68.5 years; 79% of the cases presented with an advanced-stage disease (III-IV), 48% with extranodal lesions, and 14% with an hemophagocytic lymphohistiocytosis (HLH) (8 at diagnosis and 1 on therapy). A total of 46 cases presented a polymorphic pattern, and 21 were monomorphic. All had a non-germinal center B phenotype, with the majority of tumor cells expressing CD30 and programmed death ligand 1 (98% and 95%, respectively). Type II and III EBV latency was seen in 88% and 12% of the cases, respectively. Patients were treated with immunochemotherapy (59%) or chemotherapy (22%), and 19% received palliative care due to advanced age and altered performance status. After a median follow-up of 48 months, progression-free survival (PFS) and overall survival (OS) at 5 years were 52.7% and 54.8%, respectively. Older age (>50 years) and HLH were associated with shorter PFS and OS in multivariate analysis (PFS: hazard ratio [HR], 14.01; 95% confidence interval [CI], 2.34-83.97; and HR, 5.78; 95% CI, 2.35-14.23; OS: HR, 12.41; 95% CI, 1.65-93.53; and HR, 6.09; 95% CI, 2.42-15.30, respectively). Finally, using a control cohort of 425 EBV− DLBCL-NOS, EBV positivity was associated with a shorter OS outcome within patients >50 years (5-year OS, 53% [95% CI, 38.2-74] vs 60.8% [95% CI, 55.4-69.3], P = .038), but not in younger patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|